Navigation Links
NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Date:5/27/2010

ed into the human body. The response is strong enough to destroy transplanted cells and tissues within hours. NewLink's HyperAcute immunotherapy exploits this hyperacute antigen-antibody response to educate a patient's immune system to attack and destroy the patient's own unmodified cancer cells.

The company's HyperAcute products are composed of irradiated, allogeneic (off the shelf), whole cancer cells that have been genetically modified to add alpha-Gal residues to cell-surface lipids and proteins. The alpha-Gal epitopes function as a molecular adjuvant, effectively harnessing the xenotransplant rejection mechanism.

About HyperAcute-Pancreas Immunotherapy

HyperAcute-Pancreas immunotherapy consists of two equal cell doses of allogeneic pancreatic cancer cell lines engineered to express the murine alpha-Gal gene. Although cells making up naturally occurring pancreatic tumors in patients do not express alpha-Gal, they share other molecules including new tumor-specific and tumor -associated antigens, with the genetically altered pancreatic cancer cells introduced by the immunotherapy. Those similarities are believed to allow the antibodies and immune cells targeting alpha-Gal to redirect their attack and destroy patient's own tumor cells.

About Pancreatic Cancer

Cancer of the pancreas is the fourth leading cause of cancer death in the United States, killing more than 35,000 Americans in 2009. The disease is divided into two broad subtypes based on histological classification: pancreatic endocrine tumors are diagnosed in 5 percent of cases, and pancreatic adenocarcinoma accounts for the remaining 95 percent. Incidence and age-adjusted mortality rates of pancreatic adenocarcinoma are nearly equal, meaning the disease is almost universally fatal. Pancreatic cancer is
'/>"/>

SOURCE NewLink Genetics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NewLink Genetics Corporation Closes $7.5 Million Financing
2. NewLink Genetics to Present Phase 2 Data on HyperAcute(R)-Pancreas Immunotherapy at the American Society of Clinical Oncology Annual Meeting
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
5. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
6. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
9. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A case ... collaboration between the school,s bioengineering department and the ... the Intel® Software Academic Program, UCSD,s research focuses ... the human body.  Photo - ... exhibits the work of Dr. Todd P. ...
(Date:8/19/2014)... 2014 Shimadzu Scientific Instruments has ... and Nexera-i, adding to the company’s extensive line-up ... an intuitive operating environment, and full automation, the ... workflow for conventional to ultra-high-speed analysis. ... intelligent design so users can begin building the ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic ... company developing novel anti-infective biologic and drug programs ... diseases, announced today that its novel C. ... the 54 th Interscience Conference on Antimicrobial ... Washington D.C. Synthetic ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... YORK, March 21, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... "AOBO"), a pharmaceutical company dedicated to improving health through ... of prescription and over the counter ("OTC") products, announced ... 15, 2010, that its board of directors authorized a ...
... Md., March 21, 2011 United Therapeutics Corporation ... enrollment in its FREEDOM-C(2) registration trial was completed ... a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study ... diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients ...
... Recent events in Japan have caused the world to ... be a cause for concern – especially if radiation ... proliferating cells of the body. Cells of the hematopoietic ... two such cell types. Damage to these cells initiates ...
Cached Biology Technology:American Oriental Bioengineering Announces US$20 Million Share Repurchase Program 2United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:8/20/2014)... Aug. 20, 2014 George E. Fox, a John and ... of Houston (UH), was named a fellow in the International ... , Fox is one of four members two ... chosen as fellows in 2014. Fellows are elected every ... more than 500 members from more than 20 countries, the ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Even healthy pregnant women can be at risk for ... Reserve University began to understand which bacteria from the 700 ... health problem of preterm and stillbirths. Yiping Han ... Dental Medicine led the study, which found several new bacteria ...
... laboratories, two Dartmouth biologists have performed one of the largest ... population. Their results, published online on May 9 by the ... more important than predation by birds and snakes when it ... Tennyson wrote that nature is ,red in tooth and claw, ...
... May 7, 2010 In findings that advance scientists, ... from The Scripps Research Institute has shed light on a ... other lysosomal storage diseases. The findings were published in ... Biology on May 9, 2010. "This study is ...
Cached Biology News:Even healthy pregnant women need to worry about oral bacteria 2Researchers use entire islands in the Bahamas to test survival of the fittest 2Scripps research scientists shed light on potential treatment for Gaucher's disease 2Scripps research scientists shed light on potential treatment for Gaucher's disease 3Scripps research scientists shed light on potential treatment for Gaucher's disease 4
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... DTT White solid. ... Purity: ≥99% by titration. ... Absorbance: (100 mM, 280 nm):≤0.05. ... or H 2 O. RTECS ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: